GM-CSF, CSF2 (Human Granulocyte-macrophage colony-stimulating factor)
Prices from £199 (50μg ) – For larger quantities, please contact us.
Product name: Human Granulocyte-macrophage colony-stimulating factor (GM-CSF, CSF2)
Product description: Recombinant Full-length Human Granulocyte-macrophage colony-stimulating factor (GM-CSF, CSF2) produced in Nicotiana benthamiana by Agrobacterium-mediated transient expression.
Host species: Nicotiana benthamiana
Molecular weight: 16.3 kDa + Glycosylation
Tag: C-terminal His-tag
Uses: For in vitro research use only. Not for human in vivo or therapeutic use.
Relevance: Granulocyte-macrophage colony-stimulating factor (GM-CSF)1 is a cytokine that stimulates the proliferation, maturation, and survival of multiple hematopoietic precursor cell types from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes2. GM-CSF has been shown to be secreted by a number of different cell types including fibroblasts, stromal cells, epithelial cells, endothelial cells and hematopoietic cells3. Recombinant GM-CSF is widely used in many cell culture applications including the differentiation of iPSCs into hematopoietic cells4.
Purity: 99 % as shown by SDS-PAGE
Biological activity: Not tested.
Endotoxin: Not tested.
Formulation: Lyophilized from PBS pH7.4, 175 mM Trehalose.
Shipping: Recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Stability & Storage: See COA for detailed storage instructions. Lyophilized materials are stable for up to twelve months from date of receipt at -70℃.
It is recommended that reconstituted protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution: A hardcopy of COA with reconstitution instructions is included with the product.
Contact us for more information.
- Becher B, Tugues S, Greter M. GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation. Immunity. 45(5):963-973. (2016).
- Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol. 12(1):37-48. (2016).
- Lachmann N, Ackermann M, Frenzel E, Liebhaber S, Brennig S, Happle C, Hoffmann D, Klimenkova O, Lüttge D, Buchegger T, Kühnel MP, Schambach A, Janciauskiene S, Figueiredo C, Hansen G, Skokowa J, Moritz T. Large-scale hematopoietic differentiation of human induced pluripotent stem cells provides granulocytes or macrophages for cell replacement therapies. Stem Cell Reports. 4(2):282-96. (2015).